Artal Group S.A. Lexicon Pharmaceuticals, Inc. Transaction History

Artal Group S.A.

$214 Million
Q3 2024

A detailed history of Artal Group S.A. transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Artal Group S.A. holds 136,180,481 shares of LXRX stock, worth $96.7 Million. This represents 100.0% of its overall portfolio holdings.

Number of Shares

136,180,481

Previous 175,099,384 22.23%

Holding current value

$96.7 Million

Previous $294 Million 27.32%

% of portfolio

100.0%

Previous 18.64%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$1.51 - $2.39 $58.8 Million - $93 Million	-38,918,903 Reduced 22.23%	136,180,481 $214 Million
Q2 2024 Aug 14, 2024	BUY	$1.54 - $2.28 $88.6 Million - $131 Million	57,546,100 Added 48.95%	175,099,384 $294 Million
Q2 2023 Aug 11, 2023	BUY	$2.15 - $3.49 $59.7 Million - $96.9 Million	27,775,050 Added 30.94%	117,553,284 $269 Million
Q3 2022 Nov 14, 2022	BUY	$1.94 - $3.43 $36.1 Million - $63.8 Million	18,599,870 Added 26.13%	89,778,234 $215 Million
Q4 2020 Feb 11, 2021	BUY	$1.05 - $3.67 $11.5 Million - $40.1 Million	10,937,500 Added 18.16%	71,178,364 $243 Million
Q2 2018 Aug 10, 2018	BUY	$7.8 - $13.69 $15.3 Million - $26.9 Million	1,966,214 Added 3.37%	60,240,864 $723 Million
Q4 2017 Feb 09, 2018	BUY	$8.77 - $12.28 $6.64 Million - $9.29 Million	756,673 Added 1.32%	58,274,650 $576 Million
Q3 2017 Nov 08, 2017	BUY	$12.17 - $16.3 $700 Million - $938 Million	57,517,977	57,517,977 $707 Million

Others Institutions Holding LXRX

# of Institutions

141

Shares Held

238M

Call Options Held

459K

Put Options Held

133K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $134M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.

Account